Patents by Inventor Raphael Clynes

Raphael Clynes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092911
    Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 21, 2024
    Applicant: Bristol-Myers Squibb Company
    Inventors: James NOVOTNY, Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
  • Patent number: 11806555
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: July 19, 2022
    Date of Patent: November 7, 2023
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 11807686
    Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: November 7, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
  • Publication number: 20230111697
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Application
    Filed: April 6, 2022
    Publication date: April 13, 2023
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Publication number: 20230074793
    Abstract: Provided herein, in certain aspects, are methods of treating a cancer in a subject, comprising administering a bispecific anti-CTLA4Ă—anti-PD1 antibody to the subject.
    Type: Application
    Filed: August 5, 2022
    Publication date: March 9, 2023
    Applicant: XENCOR, INC.
    Inventors: Barbara HICKINGBOTTOM, Paul FOSTER, Raphael CLYNES, Ying DING, Lei BAO, Catherine AVERSA-FLEENER
  • Publication number: 20230043374
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Application
    Filed: July 19, 2022
    Publication date: February 9, 2023
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 11512122
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 29, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • Patent number: 11298570
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: April 12, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Publication number: 20210261666
    Abstract: The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-Ll positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
    Type: Application
    Filed: May 30, 2018
    Publication date: August 26, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventors: James NOVOTNY, JR., Nils LONBERG, Cyrus HEDVAT, Raphael CLYNES, Darren LOCKE, John P. COGSWELL, Jeffrey JACKSON, Christopher HARBISON, Robin EDWARDS
  • Patent number: 10994157
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: May 4, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Publication number: 20210070824
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Application
    Filed: May 15, 2020
    Publication date: March 11, 2021
    Inventors: Matthew Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • Publication number: 20200237635
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 30, 2020
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Publication number: 20190262250
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Application
    Filed: March 12, 2019
    Publication date: August 29, 2019
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 10265258
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 23, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Publication number: 20190072541
    Abstract: The presently disclosed subject matter relates to biomarkers allowing for improved diagnosis and prognosis of alopecia areata as well as effective treatments for the disease, including methods that incorporate biomarkers capable of identifying patient sub-populations that will respond to such treatments and methods that incorporate biomarkers capable of tracking the progress of such treatments.
    Type: Application
    Filed: August 15, 2016
    Publication date: March 7, 2019
    Inventors: Angela Christiano, Raphael Clynes
  • Publication number: 20180291378
    Abstract: The presently disclosed subject matter relates, in certain embodiments, to compositions and methods for the inhibition of the JAK-STAT pathway in order to induce hair growth. In certain embodiments, the presently disclosed subject matter relates to topical treatments with small molecule inhibitors of the JAK-STAT pathway to induce hair growth.
    Type: Application
    Filed: May 9, 2016
    Publication date: October 11, 2018
    Inventors: Angela Christiano, Raphael Clynes
  • Patent number: 9895301
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: February 20, 2018
    Assignee: The Trustees of Columbia University in The City of New York
    Inventors: Angela M. Christiano, Raphael Clynes
  • Publication number: 20180021235
    Abstract: The invention provides for methods for treating a hiar loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Application
    Filed: August 4, 2017
    Publication date: January 25, 2018
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 9763866
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 19, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Angela M. Christiano, Raphael Clynes
  • Patent number: 9737469
    Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 22, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Angela M. Christiano, Raphael Clynes